EntreMed scientists report potent antiangiogenic effects in preclinical studies of recombinant human Endostatin and Angiostatin protein at the American Association for Cancer Research Annual Meeting.
In an American Association for Cancer Research mini-symposium on angiogenesis, EntreMed's vice president for preclinical research, Dr. B. Kim Lee Sim presented an abstract entitled "Potent Inhibition of Experimental Metastases and Primary Tumors by Recombinant Human Endostatin That is Suitable for Human Use." Dr. Sim reported that GMP-Endostatin protein, (clinical grade Endostatin for human use) was manufactured in quantity and shipped to Children's Hospital (Boston, MA) where it was used to treat human prostate cancer xenografts transplanted into mice. The human GMP Endostatin protein had the same activity and efficacy as EntreMed's non-GMP material used in earlier preclinical studies in the United States and Europe, and are the first data confirming the efficacy of EntreMed's clinical grade production in a preclinical model.
In a second EntreMed abstract presented at the American Association for Cancer Research mini-symposium on angiogenesis, entitled "Recombinant Human Angiostatin: Dose-Dependent Inhibition of Early and Late Stage Established Metastases in Mice," EntreMed scientists presented data showing that their recombinant Angiostatin protein markedly inhibited malignant melanoma in both early stage and late stage metastatic cancer in the lungs of mice. EntreMed researchers cloned the human Angiostatin protein and now produce it in scale-up fermentation using the yeast Pichia pastoris.
In total, EntreMed researchers gave nine presentations of the company's own research on its antiangiogenic product candidates and their respective effects in preclinical cancer models at the American Association for Cancer Research Annual Meeting, including two from the company's internal discovery program -- "Enantiomeric, Dependent Antimetastatic Activity of a Stable Thalidomide Analog," and "Tissue Factor Pathway Inhibitor Is an Inhibitor of Angiogenesis." A complete list of EntreMed's scientific study abstracts is attached.
Dr. Joanna C. Horobin, EntreMed's senior vice president of commercial development, commented on the presentations : "EntreMed is pleased to provide progress reports on our antiangiogenic product portfolio at this prestigious scientific meeting. We remain on schedule to commence Phase I safety trials of Endostatin protein later this year."
The American Association for Cancer Research is a professional society with more than 14,000 laboratory and clinical scientists engaged in cancer research in the United States, Canada and 60 other countries. Its principal activities include fostering advances in cancer and biomedical research through programs that promote scientific education and communication, meetings to present significant new discoveries in cancer and the publishing of four major peer-reviewed journals including Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation and Cancer Epidemiology, Biomarkers & Prevention.
EntreMed is a leader in the field of antiangiogenesis research, which studies the inhibition of abnormal blood vessel growth recently associated with a broad range of diseases. The company's strategy is to accelerate development of its core technologies through collaborations and sponsored research programs with university medical departments, research companies and government laboratories.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Technology Information|
|Comment:||EntreMed scientists report potent antiangiogenic effects in preclinical studies of recombinant human Endostatin and Angiostatin protein at the American Association for Cancer Research Annual Meeting.(Technology Information)|
|Publication:||BIOTECH Patent News|
|Date:||Apr 1, 1999|
|Previous Article:||AltaRex update-legal proceedings with Biomira.|
|Next Article:||SIBIA Neurosciences announces license of patented transcription based assay technology to SmithKline Beecham.|